Sandoz Group

Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystHighTarget's Fair Value

CHF 60.65

16.7% undervalued

24 Aug

CHF 50.52

34.5%

3.7%

34.5%

3.7%

Author's Valuation

CHF 60.7

16.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CHF 60.7

16.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.67%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

3.82%

Calculation

US$2.07b

Earnings '28

17.74x

PE Ratio '28

US$36.76b

Market Cap '28

US$36.76b

Market Cap '28

435.92m

No. shares '28

US$84.33

Share Price '28

US$84.33 Share Price '28

Discounted to 2025 @ 3.82% p.a.

US$75.36

Fair Value '25

US$75.36 Fair Value '25

Converted to CHF @ 0.8013 USD/CHF Exchange Rate

CHF 60.38

Fair Value '25